Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 2, 2006, Pages 503-512

  Young, Chai Lim ^a,b   Li, Lang ^a   Desta, Zeruesenay ^a   Zhao, Qianqian ^a   Rae, James M ^c   Flockhart, David A ^a   Skaar, Todd C ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Chonnam National University Medical School   (South Korea)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CYTOCHROME P450 2D6; DRUG METABOLITE; ENDOXIFEN; ESTRADIOL; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 33745939124     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.100511     Document Type: Article

References (40)

1. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, and Ford L (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91:1654-1662.
2. Clarke R, Leonessa F, Welch JN, and Skaar TC (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71.
3. Coezy E, Borgna JL, and Rochefort H (1982) Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42:317-323.
4. Coser KR, Chesnes J, Hur JY, Ray S, Isselbacher KJ, and Shioda T (2003) Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc Natl Acad Sci USA 100:13994-13999.
5. Creighton CJ, Cordero KE, Larios JM, Miller RS, Johnson MD, Chinnaiyan AM, Lippman ME, and Rae JM (2006) Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol 7:R28.
6. Crewe HK, Notley LM, Wunsch RM, Lennard MS, and Gillam EM (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869-874.
7. Desta Z, Ward BA, Soukhova NV, and Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075.
8. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, and Katzenellenbogen BS (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562-4574.
9. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, and Katzenellenbogen BS (2004) Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522-1533.
10. Furr BJ and Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205.
11. Gaedigk A, Bradford LD, Marcucci KA, and Leeder JS (2002) Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 72:76-89.
12. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, and Reid IR (1995) The effect of the antiestrogen tamoxifen on bone-mineral density in normal late postmenopausal women. Am J Med 99:636-641.
13. Gunther EC, Stone DJ, Gerwien RW, Bento P, and Heyes MP (2003) Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc Natl Acad Sci USA 100:9608-9613.
14. Hong P and Wing HW (2005) GeneNotes - a novel information management software for biologists. BMC Bioinformatics 19:185-193.
15. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, and Hayashi S (2002) Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 29:175-192.
16. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39.
17. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, and Skaar TC (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159.
18. Jordan VC (1982) Metabolites of tamoxifen in animal and man: identification, pharmacology, and significance. Breast Cancer Res Treat 2:123-138.
19. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, and Mangel WF (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112-119.
20. Lauritsen KJ, List HJ, Reiter R, Wellstein A, and Riegel AT (2002) A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene 21:7147-7155.
21. Lee KH, Ward BA, Desta Z, Flockhart DA, and Jones DR (2003) Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 791:245-253.
22. Lien EA, Solheim E, Kvinnsland S, and Ueland PM (1988) Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48:2304-2308.
23. Lien EA, Solheim E, and Ueland PM (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51:4837-4844.
24. Lim YC, Desta Z, Flockhart DA, and Skaar TC (2005) Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471-478.
25. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, and Chappell RJ (1994) Effects of tamoxifen on cardiovascular risk-factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86:1534-1539.
26. Mauvais-Javis P, Baudot N, Castaigne D, Banzet P, and Kuttenn F (1986) trans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res 46:1521-1525.
27. May FE, Johnson MD, Wiseman LR, Wakeling AE, Kastner P, and Westley BR (1989) Regulation of progesterone receptor mRNA by oestradiol and antioestrogens in breast cancer cell lines. J Steroid Biochem 33:1035-1041.
28. May FE and Westley BR (1986) Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells. Cancer Res 46:6034-6040.
29. May FE and Westley BR (1988) Identification and characterization of estrogen-regulated RNAs in human breast cancer cells. J Biol Chem 263:12901-12908.
30. McClintick JN, Jerome RE, Nicholson CR, Crabb DW, and Edenberg HJ (2003) Reproducibility of oligonucleotide arrays using small samples. BMC Genomics 4:4.
31. Meier CR and Jick H (1998) Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45:608-612.
32. Nephew KP, Ray S, Hlaing M, Ahluwalia A, Wu SD, Long X, Hyder SM, and Bigsby RM (2000) Expression of estrogen receptor coactivators in the rat uterus. Biol Reprod 63:361-367.
33. Olsen CM, Meussen-Elholm ETM, Holme JA, and Hongslo JK (2002) Brominated phenols: characterization of estrogen-like activity in the human breast cancer cell-line MCF-7. Toxicol Lett 129:55-63.
34. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45.
35. Powles TJ, Hickish T, Kanis JA, Tidy A, and Ashley S (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84.
36. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, and Elomaa I (1996) Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 14:429-433.
37. Skaar TC, Prasad SC, Sharareh S, Lippman ME, Brunner N, and Clarke R (1998) Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. J Steroid Biochem Mol Biol 67:391-402.
38. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, and Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764.
39. Thenot S, Charpin M, Bonnet S, and Cavailles V (1999) Estrogen receptor cofactors expression in breast and endometrial human cancer cells. Mol Cell Endocrinol 156:85-93.
40. Wang DY, Fulthorpe R, Liss SN, and Edwards EA (2004) Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol 18:402-411.